SynthesisFrontiers in oncology2024
Prognostic and clinicopathological significance of mucin family members expression in gastric cancer: a meta-analysis.
Synthesis in Frontiers in oncology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Mucin family members have been reported to be widely expressed in gastric carcinoma with diverse functions. Several important mucins exert the function of tumorigenesis or progression in gastric cancer (GC). Here, we conduct this meta-analysis to evaluate the association between mucin expression and clinicopathological features in GC. Methods: Literature searches were performed in PubMed, Embase, The Cochrane Library, and ISI Web of Science, and, finally, 28 studies met our criteria. Odds ratios or hazard ratios with 95% confidence intervals were calculated to evaluate the effect quantity. We analyzed the expression of MUC1, MUC2, MUC5AC, and MUC6 and their clinicopathological characteristics separately at the same time. Results: Twenty-eight studies that contain 4,603 patients were included in our meta-analysis. MUC1 was associated with gender, Lauren classification, depth of tumor invasion, TNM, vascular invasion, lymph metastasis, and lymphatic invasion, WHO grade, as well as the 5-year survival rate. MUC2 was significantly correlated with lymphatic invasion and WHO grade. MUC5AC was highly positive in gender, depth of tumor invasion, WHO grade, TNM, lymph metastasis, and lymphatic invasion. Moreover, cases with decreased MUC5AC expression were correlated with less 5-year survival. MUC6 was only related with lymphatic invasion. Conclusion: Our meta-analysis showed that MUC1 and MUC5AC had prognostic value in GC detected by immunohistochemistry. MUC1 and MUC5AC were also associated with some other significant clinicopathological parameters. Moreover, MUC2 and MUC6 also exert their influence in lymphatic invasion. However, further enlarged study awaits to verify our conclusion to deeply explore the role of mucin family members in GC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.